SCHEMBL2967433

SCHEMBL2967433

CN(C)CCCn1nc(-c2ccc3c(ccn3Cc3ccccc3Cl)c2)c2c(N)ncnc21

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 11/20 0.47
▸ PRKDC P78527 10/20 0.47
▸ PIK3CA P42336 8/20 0.47
▸ PIK3CB P42338 8/20 0.47
▸ PIK3CG P48736 8/20 0.47
▸ TGFBR1 P36897 1/20 0.46
▸ SRC P12931 10/20 0.46
▸ FYN P06241 1/20 0.44
▸ YES1 P07947 1/20 0.44
▸ LYN P07948 1/20 0.44
▸ FGR P09769 1/20 0.44
▸ ABL1 P00519 3/20 0.44
▸ EGFR P00533 2/20 0.44
▸ HCK P08631 2/20 0.44
▸ KDR P35968 2/20 0.44
▸ MTOR P42345 2/20 0.44
▸ EPHB4 P54760 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2956385 0.89 KDR (0.51) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL2969399 0.83 TGFBR1 (0.44) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL2969401 0.83 TGFBR1 (0.44) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL2961978 0.79 SRC (0.59) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL2962359 0.78 PIK3CD (0.44) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL2960164 0.77 PIK3CD (0.46) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL2960168 0.77 PIK3CD (0.46) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL2958139 0.77 TGFBR1 (0.52) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL2966182 0.76 SRC (0.56) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL2962222 0.76 EGFR (0.56) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP claimed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US claimed
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP disclosed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US disclosed
EP-1973917-A2 PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2008-10-01 — — EP disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 — — US disclosed
WO-2007079164-A2 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 PIK3CD 264/4885PRKDC 11/4885PIK3CA 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback